GdTCR Anti-CD3 Bispecific molecules(GABs) combined with costimulatory T cell engagers as novel immunotherapy against cancer

In the project we aim to increase the efficacy of the current γ9δ2-GABs. This will be done through the addition of costimulation to the GAB format as either trispecific γδTCR TCE (GAT) or adding a standalone costimulatory TCE (GAC). Additionaly we aim to assess the safety and efficacy balance for GAB, GAT and GAC to make decisions in what to take forward to the clinic.

Contact 
Jairo Lommen